Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Mesothelioma 1Melanoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Melanoma × Fecal Microbiota Transplantation × Clear all
NCT03341143 2024-10-30

Fecal Microbiota Transplant (FMT) in Melanoma Patients

University of Pittsburgh

Phase 2 Completed
20 enrolled 19 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡